Open an account

Heron Therapeutics

HRTX · NASDAQ

$0.3545−$0.0064 (−1.77%)TodayMarket closed ·
Prev close $0.3609

About HRTX

Heron Therapeutics, Inc is a biotechnology company, which engages in the development of pharmaceutical products for acute care and oncology patients. The company is headquartered in Cary, North Carolina and currently employs 128 full-time employees. Its acute care product portfolio includes ZYNRELEF, APONVIE, CINVANTI, and SUSTOL. ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low-dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is the intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist indicated for postoperative nausea and vomiting in adults. CINVANTI is an IV formulation of aprepitant, a substance NK1 receptor antagonist. SUSTOL is the first extended-release 5-HT3 receptor antagonist approved for the prevention of acute and delayed nausea and vomiting associated with both MEC and anthracycline and cyclophosphamide combination chemotherapy regimens.

Employees
128
Headquarters
Cary, North Carolina
Listed
Aug 26, 1987
Sector
Health Care
Industry
Biotechnology
Website
herontx.com

HRTX key statistics

Market cap
67.30M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
2.73M
Volume
1.48M
Open price
$0.3616
High today
$0.3859
Low today
$0.3529
52 Week high
$1.58
52 Week low
$0.261

Heron Therapeutics (HRTX) at a glance

As of Oct 20, 2026, Heron Therapeutics (HRTX) shares are priced at $0.3545, giving the company a market cap of 67.30M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.3529 and $0.3859. The current price is 0.5% above the day's low and 8.1% below its high.

Volume so far is 1.48M shares, below the average of 2.73M shares a day.

Over the past year Heron Therapeutics has ranged from $0.261 to $1.58, and now sits 7% of the way up that range.

Heron Therapeutics met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.03 per share against an estimate of $0.0102.

The average analyst price target is $2.55, 619.3% above the current price, from 2 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

0%of 2 analyst ratings say Buy
  • Buy0.0%
  • Hold100.0%
  • Sell0.0%
Price target · 4 analystsAvg $2.55
Low
$2.02
Now
$0.3545
High
$3.15

HRTX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 108.6% on average.

  1. Q3 FY24: reported -$0.03 per share against an estimate of -$0.034
  2. Q4 FY24: reported $0.02 per share against an estimate of -$0.0272
  3. Q1 FY25: reported $0.01 per share against an estimate of -$0.0068
  4. Q2 FY25: reported -$0.02 per share against an estimate of -$0.0102
  5. Q3 FY25: reported -$0.04 per share against an estimate of -$0.0153
  6. Q4 FY25: reported -$0.02 per share against an estimate of -$0.0204
  7. Q1 FY26: reported -$0.04 per share against an estimate of -$0.0153
  8. Q2 FY26: reported -$0.03 per share against an estimate of $0.0102

HRTX news

  • 12 Health Care Stocks Moving In Monday's Intraday Session

  • Press releaseGlobe Newswire

    Heron Therapeutics Announces Second Quarter 2026 Financial Results

  • Press releaseGlobe Newswire

    Heron Therapeutics to Report Second Quarter 2026 Financial Results on Monday, August 10, 2026

  • Press releaseGlobe Newswire

    U.S. District Court Issues Decision Regarding CINVANTI® Patents

  • 12 Health Care Stocks Moving In Monday's Intraday Session

  • Press releaseGlobe Newswire

    Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance

  • Press releaseGlobe Newswire

    Heron Therapeutics to Report First Quarter 2026 Financial Results on Monday, May 11, 2026

  • Press releaseGlobe Newswire

    Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results

Similar companies

Companies in the same industry as Heron Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.